BioCentury | Mar 31, 2021
Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

...and then buying up, early cancer detection companies.A month after the Illumina-Grail deal was announced, Exact Sciences Corp....
...that the FTC would consult specifically with the industry.” Karen Tkach Tuzman Illumina Inc. Grail Inc. Thrive Earlier Detection Corp. Exact Sciences Corp. federal...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...Prometheus Biosciences Inc. named Mark Stenhouse COO. He was GM of the screening business at Exact Sciences Corp....
BioCentury | Mar 6, 2021
Finance

CRISPR stocks track ETFs lower: Data Byte

...which have fallen 31% in the past month.Other major ARK ETF holdings include diagnostics company Exact Sciences Corp....
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...NASDAQ:ILMN). A month later, Grail competitor Thrive Earlier Detection Corp. was acquired by early detection pioneer Exact Sciences Corp....
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Detection Corp.’s $257 million series B in July followed by its $2.2 billion takeout by Exact Sciences Corp....
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...Roche buyout of Freenome be next? By Karen Tkach Tuzman, Associate Editor Thrive’s acquisition by Exact Sciences...
...company’s Cologuard, to recommend screening five years earlier.Tuesday’s deal, valued at up to $2.2 billion, saw Exact Sciences Corp....
...than 50, and including Exact Sciences' Cologuard as a method for all average-risk patients 45-75 years old.Exact Sciences...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...LDT) in the U.S. in 2021, and leads among at least seven U.S. competitors, including  Exact Sciences Corp....
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...see Emerging Company Profile: “Applying AAV9 Across the CNS”).Conroy’s Cowen presentation lifts Exact Sciences Cancer screening company Exact Sciences...
...Conroy told the Cowen Liquid Biopsy Summit. The stock rose $19.96 (27%) to $94.04, giving Exact Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...estimated adherence rates of 33-43% for stool-based tests.Exact Sciences Corp....
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...committee meeting to discuss the application. Trio of studies back Exact’s personalized breast cancer test Exact Sciences Corp....
... SubQ ofatumumab, subcutaneous ofatumumab ATB-346 maralixibat (SHP625, lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck...
Items per page:
1 - 10 of 249
BioCentury | Mar 31, 2021
Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

...and then buying up, early cancer detection companies.A month after the Illumina-Grail deal was announced, Exact Sciences Corp....
...that the FTC would consult specifically with the industry.” Karen Tkach Tuzman Illumina Inc. Grail Inc. Thrive Earlier Detection Corp. Exact Sciences Corp. federal...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...Prometheus Biosciences Inc. named Mark Stenhouse COO. He was GM of the screening business at Exact Sciences Corp....
BioCentury | Mar 6, 2021
Finance

CRISPR stocks track ETFs lower: Data Byte

...which have fallen 31% in the past month.Other major ARK ETF holdings include diagnostics company Exact Sciences Corp....
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...NASDAQ:ILMN). A month later, Grail competitor Thrive Earlier Detection Corp. was acquired by early detection pioneer Exact Sciences Corp....
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...Detection Corp.’s $257 million series B in July followed by its $2.2 billion takeout by Exact Sciences Corp....
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...Roche buyout of Freenome be next? By Karen Tkach Tuzman, Associate Editor Thrive’s acquisition by Exact Sciences...
...company’s Cologuard, to recommend screening five years earlier.Tuesday’s deal, valued at up to $2.2 billion, saw Exact Sciences Corp....
...than 50, and including Exact Sciences' Cologuard as a method for all average-risk patients 45-75 years old.Exact Sciences...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...LDT) in the U.S. in 2021, and leads among at least seven U.S. competitors, including  Exact Sciences Corp....
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...see Emerging Company Profile: “Applying AAV9 Across the CNS”).Conroy’s Cowen presentation lifts Exact Sciences Cancer screening company Exact Sciences...
...Conroy told the Cowen Liquid Biopsy Summit. The stock rose $19.96 (27%) to $94.04, giving Exact Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...estimated adherence rates of 33-43% for stool-based tests.Exact Sciences Corp....
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...committee meeting to discuss the application. Trio of studies back Exact’s personalized breast cancer test Exact Sciences Corp....
... SubQ ofatumumab, subcutaneous ofatumumab ATB-346 maralixibat (SHP625, lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck...
Items per page:
1 - 10 of 249